Indication: Lung Cancer
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinu
Sub-indication: Lung Cancer
Drug Study
Principal Investigator: Adam Lye, M.D.Norton Cancer Institute
Sponsor: Mirati Therapeutics, Inc
Learn more at ClinicalTrials.gov
Email for more information: Lung-NCIResearch@nortonhealthcare.org